Dyadic International, Inc. (DYAI)
Dyadic International, Inc. is a biotechnology company focused on developing and selling enzymes and proteins. Their patented C1 platform is used for manufacturing human and animal vaccines and drugs.
Company Overview
Dyadic International leverages its innovative C1 platform for efficient protein production, targeting the development of vaccines and therapeutics; a compelling opportunity for investors seeking exposure to disruptive biotechnology with a focus on addressing unmet needs in human and animal health.
Investment Thesis
Dyadic International presents a compelling investment opportunity due to its innovative C1 platform, which offers a potentially disruptive approach to biologics manufacturing. The successful validation of DYAI-100 in Phase 1 clinical trials could serve as a significant catalyst, demonstrating the platform's ability to produce effective vaccines against COVID-19 variants. The company's collaborations with VTT, Biotechnology Developments for Industry in Pharmaceuticals, and Syngene International further enhance its R&D capabilities and expand its market reach. With a market capitalization of $0.03 billion, Dyadic offers substantial upside potential if it can successfully commercialize its C1 platform and secure additional partnerships. The company's gross margin of 42.2% indicates a strong potential for profitability as it scales its operations.
Key Highlights
- Market capitalization of $0.03 billion, indicating potential for growth if the C1 platform is successfully commercialized.
- Gross margin of 42.2% demonstrates the potential for strong profitability as the company scales its operations.
- DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate, is currently in Phase 1 clinical trials, representing a key milestone for the company.
- Research and development agreements with VTT Technical Research Centre of Finland, Ltd., expanding the company's research capabilities.
- Collaboration with Syngene International Limited, enhancing the company's ability to develop and commercialize its products.
Competitors
Strengths
- Patented C1 protein production platform.
- Efficient and cost-effective protein production.
- Experienced management team.
- Strategic partnerships.
Weaknesses
- Limited financial resources.
- Dependence on C1 platform.
- Early stage of development.
- Small number of employees.
Catalysts
- Upcoming: Completion of Phase 1 clinical trials for DYAI-100.
- Ongoing: Expansion of C1 platform applications.
- Ongoing: Strategic partnerships and collaborations.
- Ongoing: Licensing of C1 platform to other companies.
Risks
- Potential: Clinical trial failures.
- Potential: Competition from established biotechnology companies.
- Potential: Regulatory hurdles.
- Ongoing: Limited financial resources.
- Potential: Intellectual property infringement.
Growth Opportunities
- Expansion of C1 Platform Applications: Dyadic can expand the applications of its C1 platform beyond COVID-19 vaccines to develop a broader range of biologics, including monoclonal antibodies, biosimilars, and other therapeutic proteins. The global market for biologics is projected to reach $420 billion by 2028, providing a significant growth opportunity for Dyadic. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: Dyadic can pursue additional strategic partnerships and collaborations with pharmaceutical companies and research institutions to accelerate the development and commercialization of its products. These partnerships can provide access to funding, expertise, and market channels. Timeline: Ongoing.
- Geographic Expansion: Dyadic can expand its geographic presence by establishing operations in key markets, such as Europe and Asia. This will allow the company to tap into new customer segments and increase its revenue streams. Timeline: 2027-2028.
- Development of Animal Health Products: Dyadic can leverage its C1 platform to develop and commercialize animal health products, including vaccines and therapeutics for livestock and companion animals. The global animal health market is estimated to reach $50 billion by 2027, representing a significant growth opportunity for Dyadic. Timeline: 2026-2027.
- Licensing of C1 Platform: Dyadic can license its C1 platform to other biotechnology companies and research institutions, generating revenue and expanding the reach of its technology. This can provide a recurring revenue stream and reduce the company's reliance on product sales. Timeline: Ongoing.
Opportunities
- Expanding applications of C1 platform.
- Strategic partnerships and collaborations.
- Geographic expansion.
- Development of animal health products.
Threats
- Competition from established biotechnology companies.
- Regulatory hurdles.
- Clinical trial failures.
- Intellectual property infringement.
Competitive Advantages
- Patented C1 protein production platform.
- Efficient and cost-effective protein production capabilities.
- Expertise in developing and manufacturing biologics.
- Strategic partnerships with leading research institutions and pharmaceutical companies.
About
Dyadic International, Inc., founded in 1979 and headquartered in Jupiter, Florida, is a biotechnology platform company dedicated to the development, production, and sale of enzymes and other proteins. The company's core technology is its patented and proprietary C1 platform, a fungal expression system that enables the efficient and cost-effective production of a wide range of biologics. This platform is utilized for research, development, and commercial activities focused on manufacturing human and animal vaccines and drugs, including virus-like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. Dyadic's lead product candidate is DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate currently in Phase 1 clinical trials. This trial aims to validate the C1 platform as a viable solution for developing next-generation multivariant COVID-19 vaccines. Dyadic collaborates with various organizations, including VTT Technical Research Centre of Finland, Ltd., Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., and Syngene International Limited, to expand its research and development capabilities and accelerate the commercialization of its products.
What They Do
- Develops and produces enzymes and other proteins.
- Utilizes the patented C1 platform for protein production.
- Conducts research and development for human and animal vaccines and drugs.
- Manufactures virus-like particles and antigens.
- Develops monoclonal antibodies and other therapeutic proteins.
- Offers DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate.
Business Model
- Develops and licenses its C1 protein production platform.
- Generates revenue through research and development agreements.
- Aims to commercialize vaccines and therapeutic proteins.
- Partners with other companies for manufacturing and distribution.
Industry Context
Dyadic International operates in the biotechnology industry, a sector characterized by rapid innovation and significant growth potential. The market for biologics, including vaccines and therapeutic proteins, is expanding due to the increasing prevalence of chronic diseases and the growing demand for personalized medicine. The competitive landscape includes established pharmaceutical companies and emerging biotechnology firms, all vying for market share. Dyadic's C1 platform offers a unique value proposition by enabling more efficient and cost-effective production of biologics compared to traditional methods. This positions Dyadic to capitalize on the growing demand for affordable and accessible healthcare solutions.
Key Customers
- Pharmaceutical companies seeking efficient protein production.
- Biotechnology companies developing vaccines and therapeutics.
- Research institutions conducting biological research.
- Animal health companies developing animal vaccines and therapeutics.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1M | -$2M | $-0.06 |
| Q2 2025 | $463,449 | -$2M | $-0.06 |
| Q1 2025 | $183,100 | -$2M | $-0.07 |
| Q4 2024 | $817,376 | -$2M | $-0.05 |
Source: Company filings
Chart & Info
Price Chart
Dyadic International, Inc. (DYAI) stock price: $0.80 (+0.00, +0.00%)
Why Bull
- •Recent insider buying suggests confidence in Dyadic's future prospects, aligning interests with shareholders.
- •The community is buzzing about potential partnerships leveraging Dyadic's C1 platform for novel applications.
- •Positive sentiment indicates the market is receptive to Dyadic's focus on sustainable protein production.
- •The narrative around biotech innovation is strong, potentially benefiting companies like Dyadic.
Why Bear
- •Lack of concrete partnership announcements leaves some investors skeptical about immediate revenue generation.
- •Community concerns linger regarding the scalability of Dyadic's technology to meet large-scale demand.
- •Market perception may be influenced by broader economic uncertainty impacting smaller biotech companies.
- •Bearish sentiment stems from the long development timelines inherent in the biotech industry, requiring patience.
Latest News
-
Dyadic Applied Biosolutions Announces Commercial Launch Of AlbuFree DX, rHA Product Produced Using Dyadic's Proprietary Filamentous Fungal Expression Technology
benzinga · Feb 17, 2026
-
Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
Yahoo! Finance: DYAI News · Feb 17, 2026
-
Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
GlobeNewswire · Feb 17, 2026
-
Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
globenewswire.com · Feb 17, 2026
Technical Analysis
Rationale
AI-generated technical analysis for DYAI including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Dyadic International, Inc. (DYAI) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for DYAI.
Make a Prediction
Set your price target for Dyadic International, Inc. (DYAI), choose a timeframe, and track your prediction accuracy.
Current price: $0.80
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DYAI.
Price Targets
Wall Street price target analysis for DYAI.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 6/100
Revenue increased 20.6% YoY, reflecting moderate but steady business growth.
-
Gross Margin 8/100
Gross margin at 42.2% indicates good unit economics and healthy profitability per sale.
-
Operating Leverage 6/100
Revenue growth is driving operating leverage, meaning profits can grow faster than costs.
-
Cash Runway 5/100
Limited cash of $7M could constrain flexibility; watch for dilution risk or debt issuance.
-
R&D Intensity 10/100
Investing 58.5% of revenue in R&D signals heavy commitment to innovation and future product pipeline.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Low turnover of 0.14% creates liquidity risk; large orders may impact the stock price.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates DYAI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Dyadic Applied Biosolutions Announces Commercial Launch Of AlbuFree DX, rHA Product Produced Using Dyadic's Proprietary Filamentous Fungal Expression Technology
Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
Frequently Asked Questions
What does Dyadic International, Inc. do?
Dyadic International is a biotechnology company that specializes in the development and production of enzymes and other proteins using its patented C1 platform. This platform enables the efficient and cost-effective manufacturing of biologics, including vaccines and therapeutic proteins. The company focuses on developing solutions for both human and animal health, with its lead product candidate, DYAI-100, being a SARS-CoV-2-RBD antigen vaccine. Dyadic aims to partner with pharmaceutical companies and research institutions to commercialize its products and expand the reach of its C1 platform.
Is DYAI stock a good buy?
DYAI stock presents a speculative investment opportunity with high potential upside and significant risks. The company's C1 platform offers a unique value proposition in the biologics manufacturing space, but its success depends on the successful completion of clinical trials and commercialization of its products. With a market capitalization of $0.03 billion and negative P/E ratio of -4.00, DYAI is a high-risk, high-reward investment. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in DYAI.
What are the main risks for DYAI?
The main risks for Dyadic International include the potential for clinical trial failures, competition from established biotechnology companies, regulatory hurdles, and limited financial resources. The company's success depends on the successful development and commercialization of its products, which is subject to significant regulatory and clinical risks. Additionally, Dyadic faces competition from larger and more established biotechnology companies with greater financial resources. The company's limited financial resources also pose a risk to its ability to fund its research and development activities.
Is DYAI a good stock to buy?
Whether DYAI is a good investment depends on your financial goals, risk tolerance, and investment horizon. Review the Investment Thesis, SWOT analysis, and Risk sections on this page. Always do your own research and consult a financial advisor before investing.
What is the DYAI MoonshotScore?
MoonshotScore is our proprietary AI-powered rating system that evaluates stocks based on growth potential, financial health, market momentum, and risk factors. It helps investors quickly identify high-potential opportunities. Check the MoonshotScore badge on this page for the current rating.
How often is DYAI data updated?
Stock prices are updated in real-time during market hours (9:30 AM - 4:00 PM ET). Company fundamentals, analyst ratings, and AI insights are refreshed daily. News is updated continuously throughout the day.
What are the growth catalysts for DYAI?
Growth catalysts vary by company and may include new product launches, market expansion, earnings surprises, partnerships, or industry tailwinds. Check the Catalysts section on this page for specific drivers relevant to Dyadic International, Inc..
Who are DYAI's main competitors?
Dyadic International, Inc.'s competitors depend on its industry and market segments. Check the Competitors section on this page for a list of direct competitors and how DYAI compares.
What do analysts say about DYAI?
Analyst ratings and price targets for DYAI are aggregated from multiple sources. Check the Analyst Consensus tab for buy/hold/sell ratings and the current consensus price target.
What is DYAI's market cap?
Market capitalization reflects the total market value of DYAI's outstanding shares. Check the Key Statistics section at the top of this page for the current market cap and other key financial metrics.
How has DYAI stock performed recently?
Check the Chart & Info tab for DYAI's recent price action, including daily, weekly, and monthly performance charts with technical indicators.
What are the risks of investing in DYAI?
Every stock carries risk. Check the Risks and Weaknesses sections on this page for DYAI-specific risk factors. Consider macroeconomic conditions, industry trends, and company-specific challenges.
Are insiders buying or selling DYAI?
Insider activity can signal management confidence. Check the Insider Flow tab for recent insider buys, sells, and exercise transactions for DYAI.
Is DYAI a good stock for beginners?
Dyadic International, Inc. (DYAI) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is DYAI for first-time investors?
Every stock carries risk, including Dyadic International, Inc. (DYAI). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like DYAI.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Stock data pending update.